|Slideshows|July 5, 2018

The Brave New World of Inflammation

The immune-brain loop: a world where more and more clinicians boldly go-and thrive-among new discoveries.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Next Generation Pharmacotherapies for Mood and Anxiety Disorders: An ASCP Poster Presentation Recap

ByAlana King

June 11th 2026

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

ByLeah Kuntz,AJ Cannon, MD

June 10th 2026

Predicting Relapse in Treatment-Resistant Depression: Findings From New Esketamine Analysis

ByLeighann Forbes, PhD

June 8th 2026

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

ByLeah Kuntz

June 4th 2026

Research Frontiers in Ketamine and Esketamine for Treatment-Resistant Depression

ByMorgan Hardy, MD,William Li, MD

June 2nd 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

The Brave New World of Inflammation

Related Content

Next Generation Pharmacotherapies for Mood and Anxiety Disorders: An ASCP Poster Presentation Recap

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

Predicting Relapse in Treatment-Resistant Depression: Findings From New Esketamine Analysis

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

Research Frontiers in Ketamine and Esketamine for Treatment-Resistant Depression

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

Artificial Intelligence in Psychopharmacology: Promise and Pitfalls, With Roy Perlis, MD

Monoamines: A Full House

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings

Predicting Relapse in Treatment-Resistant Depression: Findings From New Esketamine Analysis